Reported complications described in some GLP-1 drug claims have included: Severe or persistent gastrointestinal symptoms , such as ongoing nausea, vomiting, or abdominal pain Delayed stomach emptying (gastroparesis) , which has been described by some individuals as involving bloating, nausea, vomiting, or difficulty tolerating food Intestinal complications , including reduced bowel activity (ileus), which may involve abdominal discomfort, cramping, or vomiting Gallbladder-related conditions , such as gallstones or gallbladder inflammation Blood-clot-related conditions , including deep vein thrombosis or pulmonary embolism, described in some reports and legal filings Vision-related problems , including reports involving non-arteritic anterior ischemic optic neuropathy (NAION) discussed in connection with semaglutide in certain contexts Not everyone who takes a GLP-1 medication experiences these issues, and the relationship between GLP-1 drugs and reported complications continues to be evaluated in legal proceedings
Compounded semaglutide and tirzepatide are also accessible through licensed Canadian 503A compounding pharmacies, offering an additional route for patients seeking alternatives to branded medications
Somatostatin reduces thyrotropin stimulating hormone (TSH) and thus can cause hypothyroidism , manifesting with bradycardia and hair loss amongst other symptoms
Extra B12 is usually removed from the body within 48 hours, depending on urine volume
The triple agonist mechanism means appetite suppression builds differently than with dual agonists alone
Injections can be weekly while refills are made on follow-ups.
